pembrolizumab and nivolumab in recurrent hnscc
Published 7 years ago • 812 plays • Length 6:51Download video MP4
Download video MP3
Similar videos
-
5:34
pembrolizumab for recurrent hnscc
-
2:13
nivolumab in hnscc
-
1:00
dr. ferris on pembrolizumab and nivolumab in head and neck cancer
-
5:14
immunotherapy for recurrent hnscc
-
0:40
dr. vokes on selecting nivolumab or pembrolizumab for head and neck cancer treatment
-
1:58
dr. vokes on nivolumab, pembrolizumab approvals in head and neck cancer
-
11:47
pembrolizumab in hnscc
-
5:01
patient selection for pembrolizumab in hnscc
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
4:35
patient selection for nivolumab in hnscc
-
1:34
dr. ferris discusses nivolumab in head and neck cancer
-
2:07
study results for nivolumab and pembrolizumab in head and neck cancer
-
2:36
ca209-9ky: imrt nivolumab for recurrent head and neck squamous cell cancer
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
3:55
checkpoint inhibitors for recurrent hnscc
-
26:30
head and neck cancer treatment update: pembrolizumab, nivolumab and pd-l1 markers
-
4:24
historic perspective on recurrent hnscc
-
5:05
pembrolizumab vs. standard treatment in patients with recurrent or metastatic head and neck cancer
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc